Integrin α3β1 on Tumor Keratinocytes Is Essential to Maintain Tumor Growth and Promotes a Tumor-Supportive Keratinocyte Secretome.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
01 2021
Historique:
received: 14 02 2020
revised: 08 04 2020
accepted: 01 05 2020
pubmed: 27 5 2020
medline: 7 9 2021
entrez: 27 5 2020
Statut: ppublish

Résumé

The development of integrin-targeted cancer therapies is hindered by incomplete understanding of integrin function in tumor cells and the tumor microenvironment. Previous studies showed that mice with epidermis-specific deletion of the α3 integrin subunit fail to form skin tumors during two-step chemical tumorigenesis, indicating a protumorigenic role for integrin α3β1. Here, we generated mice with tamoxifen-inducible, epidermis-specific α3 knockout to determine the role of α3β1 in the maintenance of established tumor cells and/or the associated stroma. Genetic ablation of α3 in established skin tumors caused their rapid regression, indicating that α3β1 is essential to maintain tumor growth. Although reduced proliferation and increased apoptosis were observed in α3β1-deficient tumor cells, these changes followed a robust increase in stromal apoptosis. Furthermore, macrophages and fibulin-2 levels were reduced in stroma following α3 deletion from tumor cells. Mass spectrometric analysis of conditioned medium from immortalized keratinocytes showed that α3β1 regulates a substantial fraction of the keratinocyte secretome, including fibulin-2 and macrophage CSF1; RNA in situ hybridization showed that expression of these two genes was reduced in tumor keratinocytes in vivo. Our findings identify α3β1 as a regulator of the keratinocyte secretome and skin tumor microenvironment and as a potential therapeutic target.

Identifiants

pubmed: 32454065
pii: S0022-202X(20)31584-0
doi: 10.1016/j.jid.2020.05.080
pmc: PMC7680721
mid: NIHMS1597340
pii:
doi:

Substances chimiques

Integrin alpha3beta1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-151.e6

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR063778
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA129637
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Whitney M Longmate (WM)

Department of Surgery Albany Medical College, Albany, New York, USA.

Scott Varney (S)

Department of Surgery Albany Medical College, Albany, New York, USA.

Derek Power (D)

Department of Surgery Albany Medical College, Albany, New York, USA.

Rakshitha Pandulal Miskin (RP)

Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA.

Karl E Anderson (KE)

Department of Surgery Albany Medical College, Albany, New York, USA.

Lori DeFreest (L)

Department of Surgery Albany Medical College, Albany, New York, USA.

Livingston Van De Water (L)

Department of Surgery Albany Medical College, Albany, New York, USA; Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA.

C Michael DiPersio (CM)

Department of Surgery Albany Medical College, Albany, New York, USA; Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA. Electronic address: dipersm@mail.amc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH